ClinicalTrials.gg
CompletedNCT02641353Updated Aug 5, 2021Results posted

Study to Evaluate Bioavailability of Apremilast Oral Suspension Relative to Tablet and to Assess Effect of Food on the Pharmacokinetics (PK) of the Oral Suspension

A Phase 1 interventional study of Apremilast Tablet and Apremilast Oral Suspension in Healthy Volunteers, sponsored by Amgen. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-08-05.

Sponsored by Amgen · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to assess how much of apremilast is found in the blood unchanged when administered as an oral suspension compared to when it is administered as a tablet formulation. The effect of food on apremilast oral suspension will also be evaluated. In addition, information on the safety and tolerability of apremilast will be obtained.

Read the detailed description

This is a phase 1, open-label, randomized, three-period, six-sequence crossover study in healthy subjects. The study will consist of a screening phase, baseline (Day -1), three study periods, and a follow-up phone call. Each study period will be four days in duration (Day 1 through Day 4) followed by a five-day washout between doses.

Eligible participants will be admitted into the study center on Day -1 of study Period 1 for baseline measurements. During each study period, participants will receive a single 30 mg oral dose of apremilast on Day 1 according to the assigned treatment sequence. Participants will be confined at the study center from Day 1 of study Period 1 through Day 4 of study Period 3, including the 5 day washout between doses. All participants will be discharged from the study center on Day 4 of study Period 3 following completion of required study procedures. A follow-up phone call will occur approximately four days after the discharge from the study center.

The study will be conducted in compliance with International Conference on Harmonisation (ICH) Good Clinical Practices (GCPs).

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Apremilast
  • Healthy volunteers
  • Bioavailability
  • Food effect
  • Pharmacokinetic
03

In context

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must satisfy ALL of the following criteria to be eligible for enrollment into the study:

  1. Must understand and voluntarily sign a written (ICF) prior to any study-related procedures being performed.
  2. Must be able to communicate with the investigator, understand and comply with the requirements of the study, and agree to adhere to restrictions and examination schedules.
  3. Male and female subjects of any race between 18 to 55 years of age (inclusive), and in good health as determined by the Investigator at the time of signing the informed consent document.
  4. Have a (BMI) between 18 and 33 kg/m\^2 (inclusive).
  5. No laboratory test results as determined by the investigator.
  6. At the screening visit, must be afebrile, with supine systolic blood pressure (BP): 90 to 140 mmHg, supine diastolic BP: 50 to 90 mmHg, and pulse rate: 40 to 110 bpm. Eligibility criteria for vital signs performed during check-in and/or predose on Day 1 will be at the discretion of the Investigator.
  7. Must have a normal or clinically acceptable 12-lead (ECG). Subjects must have a value ≤ 450 msec.
  8. Requirements:

    • Must comply with the following acceptable forms of contraception. All female of (FCBP) must use one of the approved contraceptive options as described below while taking apremilast and for at least 28 days after administration of the last dose of the apremilast.
    • At the time of study entry, and at any time during the study when a FCBP's contraceptive measures or ability to become pregnant changes, the Investigator will educate the subject regarding contraception options and the correct and consistent use of effective contraceptive methods in order to successfully prevent pregnancy

    All FCBP must have a negative pregnancy test at Visits 1 and 2. All FCBP subjects who engage in activity in which conception is possible must use one of the approved contraceptive options described below:

    Option 1: Any one of the following highly effective methods: hormonal contraception (oral, injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal ligation; or partner's vasectomy; OR Option 2: Male or female condom (latex condom or non-latex condom NOT made out of natural [animal] membrane [for example, polyurethane]); PLUS one of the following additional barrier methods: (a) diaphragm with spermicide; (b) cervical cap with spermicide; or (c) contraceptive sponge with spermicide.

    Male subjects (including those who have had a vasectomy) who engage in activity in which conception is possible must use barrier contraception (latex or non-latex condoms NOT made out of natural [animal] membrane [for example, polyurethane]) while on product (IP) and for at least 28 days after the last dose of IP.

  9. Must agree to refrain from donating sperm, blood or plasma (other than for this study) while participating in this study and for at least 28 days after the last dose of investigational product.
  10. Subject is willing and able to adhere to the study visit schedule and other protocol requirements

Exclusion criteria

Exclusion Criteria:

The presence of ANY of the following will exclude any healthy subject from enrollment into the study:

  1. History of any and relevant neurological, psychiatric, gastrointestinal, renal, hepatic, cardiovascular, psychological, pulmonary, metabolic, endocrine, hematological, allergic disease, drug allergies, or other major disorders.
  2. Any condition which places the subject at unacceptable risk if he were to participate in the study, or confounds the ability to interpret data from the study.
  3. Use of any prescribed systemic or topical medication within 30 days of the first dose administration.
  4. Use of any non-prescribed systemic or topical medication (including vitamin/mineral supplements, and herbal medicines) within 14 days of the first dose administration, Any surgical or medical condition possibly affecting drug absorption, distribution, metabolism and excretion, eg, bariatric procedure, colon resection, irritable bowel syndrome, Crohn's disease, etc. Subjects with cholecystectomy and appendectomy may be included.
  5. Exposure to an drug (new chemical entity) within 30 days prior to the first dose administration or 5 half-lives of that investigational drug, if known (whichever is longer).
  6. Donated blood or plasma within 8 weeks before the first dose administration to a blood bank or blood donation center.
  7. History of drug abuse (as defined by the current version of the Diagnostic and Statistical Manual [DSM]) within 2 years before dosing, or a positive drug screen reflecting consumption of illicit drugs.
  8. History of alcohol abuse (as defined by the current version of the DSM) within 2 years before dosing, or a positive alcohol screen.
  9. Known to have hepatitis, or known to be a carrier of the surface antigen (HBsAg), or antibody (HCV Ab), or have a positive result to the test for HBsAg, HCV Ab, or (HIV) antibodies at Screening.

    -

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Treatment A: Apremilast 30 mg Tablet - Fasted

    A single oral dose of 30 mg apremilast tablet after an overnight fast.

    Drug: Apremilast Tablet

  • Experimental
    Treatment B: Apremilast 30 mg Oral Suspension - Fasted

    A single oral dose of 30 mg apremilast oral suspension formulation (6 mL) after an overnight fast.

    Drug: Apremilast Oral Suspension

  • Experimental
    Treatment C - Apremilast 30 mg Oral Suspension - Fed

    A single oral dose of 30 mg apremilast oral suspension formulation (6 mL) after a high-fat meal.

    Drug: Apremilast Oral Suspension

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of Apremilast

    Concentrations of apremilast in plasma were measured using a validated liquid chromatography tandem mass spectrometry assay.

    Time frame: Predose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60 and 72 hours after dosing on day 1 of each treatment period.

  2. Area Under the Concentration-time Curve From Time Zero to the Last Measured Time Point (AUC0-t) for Apremilast

    Concentrations of apremilast in plasma were measured using a validated liquid chromatography tandem mass spectrometry assay. AUC from time zero to the last measured time point was calculated by the linear trapezoidal method.

    Time frame: Predose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60 and 72 hours after dosing on day 1 of each treatment period.

  3. Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-∞) for Apremilast

    Concentrations of apremilast in plasma were measured using a validated liquid chromatography tandem mass spectrometry assay. AUC from time zero to infinity was calculated as (AUC0-t + Ct/λz), where Ct is the last quantifiable concentration, and λz is the apparent terminal rate constant.

    Time frame: Predose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60 and 72 hours after dosing on day 1 of each treatment period.

  4. Time to Maximum Observed Plasma Concentration (Tmax) of Apremilast

    Concentrations of apremilast in plasma were measured using a validated liquid chromatography tandem mass spectrometry assay.

    Time frame: Predose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60 and 72 hours after dosing on day 1 of each treatment period.

  5. Terminal Elimination Half-life (T1/2) of Apremilast

    Time frame: Predose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60 and 72 hours after dosing on day 1 of each treatment period.

  6. Apparent Clearance of Apremilast From Plasma After Extravascular Administration (CL/F)

    Time frame: Predose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60 and 72 hours after dosing on day 1 of each treatment period.

  7. Apparent Volume of Distribution of Apremilast During the Terminal Phase (Vz/F)

    Time frame: Predose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60 and 72 hours after dosing on day 1 of each treatment period.

  8. Lag Time (Tlag) of Apremilast

    Lag time is the delay between the time of administration and start of absorption.

    Time frame: Predose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60 and 72 hours after dosing on day 1 of each treatment period.

  9. Relative Bioavailability (F) of Apremilast Oral Suspension Formulation

    Relative bioavailability of the oral suspension formulation compared to the tablet formulation, calculated as (AUC0-∞/Dose\[oral suspension\]) / (AUC0-∞/Dose\[tablet\]) \* 100%.

    Time frame: Predose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60 and 72 hours after dosing on day 1 of each treatment period.

Secondary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events

    An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values, regardless of etiology. A treatment-emergent AE (TEAE) was defined as any AE that occurred after dosing of the study drug. A serious adverse event (SAE) is any AE occurring at any dose that: * Resulted in death; * Was life-threatening; * Required inpatient hospitalization or prolongation of existing hospitalization; * Resulted in persistent or significant disability/incapacity; * Was a congenital anomaly/birth defect; * Constituted an important medical event.

    Time frame: From first dose of study drug in treatment period 1 to 8 days after the last dose; up to 18 days.

07

Results

Posted Aug 5, 2021

Participant flow

Participants were enrolled at a single site in the United States. The study consisted of three treatment periods separated by a 5-day washout period.

Participant flow — Overall Study
MilestoneSequence 1: Treatments ACBSequence 2: Treatments CBASequence 3: Treatments BACSequence 4: Treatments ABCSequence 5: Treatments CABSequence 6: Treatments BCA
Started556666
Completed556666
Not completed000000

Outcome measures

PrimaryMaximum Observed Plasma Concentration (Cmax) of Apremilast

Concentrations of apremilast in plasma were measured using a validated liquid chromatography tandem mass spectrometry assay.

Time frame:
Predose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60 and 72 hours after dosing on day 1 of each treatment period.
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of Apremilast
ng/mLTreatment A: Apremilast 30 mg Tablet - FastedTreatment B: Apremilast 30 mg Oral Suspension - FastedTreatment C: Apremilast 30 mg Oral Suspension - Fed
Maximum Observed Plasma Concentration (Cmax) of Apremilast323 ± 34.5274 ± 32.2215 ± 33.7
Statistical analysis
  • Treatment A: Apremilast 30 mg Tablet - Fasted vs Treatment B: Apremilast 30 mg Oral Suspension - Fasted · Geometric mean ratio: 84.9 · 90% CI 77.3 to 93.2Ratio of adjusted geometric means (Treatment B / Treatment A) expressed as a percentage.
  • Treatment B: Apremilast 30 mg Oral Suspension - Fasted vs Treatment C: Apremilast 30 mg Oral Suspension - Fed · Geometric mean ratio: 78.2 · 90% CI 71.2 to 86.0Ratio of adjusted geometric means (Treatment C / Treatment B) expressed as a percentage.
PrimaryArea Under the Concentration-time Curve From Time Zero to the Last Measured Time Point (AUC0-t) for Apremilast

Concentrations of apremilast in plasma were measured using a validated liquid chromatography tandem mass spectrometry assay. AUC from time zero to the last measured time point was calculated by the linear trapezoidal method.

Time frame:
Predose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60 and 72 hours after dosing on day 1 of each treatment period.
Reported as:
Geometric mean · ng*h/mL
Area Under the Concentration-time Curve From Time Zero to the Last Measured Time Point (AUC0-t) for Apremilast
ng*h/mLTreatment A: Apremilast 30 mg Tablet - FastedTreatment B: Apremilast 30 mg Oral Suspension - FastedTreatment C: Apremilast 30 mg Oral Suspension - Fed
Area Under the Concentration-time Curve From Time Zero to the Last Measured Time Point (AUC0-t) for Apremilast3130 ± 38.92740 ± 43.13160 ± 41.3
Statistical analysis
  • Treatment A: Apremilast 30 mg Tablet - Fasted vs Treatment B: Apremilast 30 mg Oral Suspension - Fasted · Geometric mean ratio: 87.6 · 90% CI 83.0 to 92.5Ratio of adjusted geometric means (Treatment B / Treatment A) expressed as a percentage.
  • Treatment B: Apremilast 30 mg Oral Suspension - Fasted vs Treatment C: Apremilast 30 mg Oral Suspension - Fed · Geometric mean ratio: 115.3 · 90% CI 109.2 to 121.7Ratio of adjusted geometric means (Treatment C / Treatment B) expressed as a percentage.
PrimaryArea Under the Concentration-time Curve From Time Zero to Infinity (AUC0-∞) for Apremilast

Concentrations of apremilast in plasma were measured using a validated liquid chromatography tandem mass spectrometry assay. AUC from time zero to infinity was calculated as (AUC0-t + Ct/λz), where Ct is the last quantifiable concentration, and λz is the apparent terminal rate constant.

Time frame:
Predose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60 and 72 hours after dosing on day 1 of each treatment period.
Reported as:
Geometric mean · ng*h/mL
Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-∞) for Apremilast
ng*h/mLTreatment A: Apremilast 30 mg Tablet - FastedTreatment B: Apremilast 30 mg Oral Suspension - FastedTreatment C: Apremilast 30 mg Oral Suspension - Fed
Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-∞) for Apremilast3160 ± 38.72760 ± 43.23190 ± 41.3
Statistical analysis
  • Treatment A: Apremilast 30 mg Tablet - Fasted vs Treatment B: Apremilast 30 mg Oral Suspension - Fasted · Geometric mean ratio: 87.8 · 90% CI 83.2 to 92.6Ratio of adjusted geometric means (Treatment B / Treatment A) expressed as a percentage.
  • Treatment B: Apremilast 30 mg Oral Suspension - Fasted vs Treatment C: Apremilast 30 mg Oral Suspension - Fed · Geometric mean ratio: 115.0 · 90% CI 109.0 to 121.7Ratio of adjusted geometric means (Treatment C / Treatment B) expressed as a percentage.
PrimaryTime to Maximum Observed Plasma Concentration (Tmax) of Apremilast

Concentrations of apremilast in plasma were measured using a validated liquid chromatography tandem mass spectrometry assay.

Time frame:
Predose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60 and 72 hours after dosing on day 1 of each treatment period.
Reported as:
Median · hours
Time to Maximum Observed Plasma Concentration (Tmax) of Apremilast
hoursTreatment A: Apremilast 30 mg Tablet - FastedTreatment B: Apremilast 30 mg Oral Suspension - FastedTreatment C: Apremilast 30 mg Oral Suspension - Fed
Time to Maximum Observed Plasma Concentration (Tmax) of Apremilast2.00 (1.00 to 5.00)2.00 (1.50 to 5.00)5.00 (1.50 to 12.00)
Statistical analysis
  • Treatment A: Apremilast 30 mg Tablet - Fasted vs Treatment B: Apremilast 30 mg Oral Suspension - Fasted · Wilcoxon signed-rank test · p = 0.1508 · Median difference: 0.25 · 90% CI 0.00 to 0.50Median difference (Treatment B - Treatment A) calculated from the Hodges-Lehmann estimate
  • Treatment B: Apremilast 30 mg Oral Suspension - Fasted vs Treatment C: Apremilast 30 mg Oral Suspension - Fed · Wilcoxon signed-rank test · p = <0.0001 · Median difference: 2.25 · 90% CI 1.27 to 3.25Median difference (Treatment C - Treatment B) calculated from the Hodges-Lehmann estimate
PrimaryTerminal Elimination Half-life (T1/2) of Apremilast
Time frame:
Predose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60 and 72 hours after dosing on day 1 of each treatment period.
Reported as:
Geometric mean · hours
Terminal Elimination Half-life (T1/2) of Apremilast
hoursTreatment A: Apremilast 30 mg Tablet - FastedTreatment B: Apremilast 30 mg Oral Suspension - FastedTreatment C: Apremilast 30 mg Oral Suspension - Fed
Terminal Elimination Half-life (T1/2) of Apremilast7.89 ± 34.58.51 ± 31.87.54 ± 30.8
PrimaryApparent Clearance of Apremilast From Plasma After Extravascular Administration (CL/F)
Time frame:
Predose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60 and 72 hours after dosing on day 1 of each treatment period.
Reported as:
Geometric mean · L/h
Apparent Clearance of Apremilast From Plasma After Extravascular Administration (CL/F)
L/hTreatment A: Apremilast 30 mg Tablet - FastedTreatment B: Apremilast 30 mg Oral Suspension - FastedTreatment C: Apremilast 30 mg Oral Suspension - Fed
Apparent Clearance of Apremilast From Plasma After Extravascular Administration (CL/F)9.51 ± 38.710.9 ± 43.29.42 ± 41.3
PrimaryApparent Volume of Distribution of Apremilast During the Terminal Phase (Vz/F)
Time frame:
Predose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60 and 72 hours after dosing on day 1 of each treatment period.
Reported as:
Geometric mean · L
Apparent Volume of Distribution of Apremilast During the Terminal Phase (Vz/F)
LTreatment A: Apremilast 30 mg Tablet - FastedTreatment B: Apremilast 30 mg Oral Suspension - FastedTreatment C: Apremilast 30 mg Oral Suspension - Fed
Apparent Volume of Distribution of Apremilast During the Terminal Phase (Vz/F)108 ± 45.2133 ± 43.7102 ± 38.9
PrimaryLag Time (Tlag) of Apremilast

Lag time is the delay between the time of administration and start of absorption.

Time frame:
Predose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60 and 72 hours after dosing on day 1 of each treatment period.
Reported as:
Median · hours
Lag Time (Tlag) of Apremilast
hoursTreatment A: Apremilast 30 mg Tablet - FastedTreatment B: Apremilast 30 mg Oral Suspension - FastedTreatment C: Apremilast 30 mg Oral Suspension - Fed
Lag Time (Tlag) of Apremilast0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)
PrimaryRelative Bioavailability (F) of Apremilast Oral Suspension Formulation

Relative bioavailability of the oral suspension formulation compared to the tablet formulation, calculated as (AUC0-∞/Dose\[oral suspension\]) / (AUC0-∞/Dose\[tablet\]) \* 100%.

Time frame:
Predose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60 and 72 hours after dosing on day 1 of each treatment period.
Reported as:
Geometric mean · percent availability
Relative Bioavailability (F) of Apremilast Oral Suspension Formulation
percent availabilityTreatment B: Apremilast 30 mg Oral Suspension - FastedTreatment C: Apremilast 30 mg Oral Suspension - Fed
Relative Bioavailability (F) of Apremilast Oral Suspension Formulation87.6 ± 16.1101 ± 14.3
SecondaryNumber of Participants With Treatment-emergent Adverse Events

An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values, regardless of etiology. A treatment-emergent AE (TEAE) was defined as any AE that occurred after dosing of the study drug. A serious adverse event (SAE) is any AE occurring at any dose that: * Resulted in death; * Was life-threatening; * Required inpatient hospitalization or prolongation of existing hospitalization; * Resulted in persistent or significant disability/incapacity; * Was a congenital anomaly/birth defect; * Constituted an important medical event.

Time frame:
From first dose of study drug in treatment period 1 to 8 days after the last dose; up to 18 days.
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events
ParticipantsTreatment A: Apremilast 30 mg Tablet - FastedTreatment B: Apremilast 30 mg Oral Suspension - FastedTreatment C: Apremilast 30 mg Oral Suspension - Fed
Any treatment-emergent adverse event (TEAE)8106
TEAEs related to study drug474
Serious adverse events000
TEAEs leading to discontinuation000
TEAEs leading to death000

Adverse events

Collected over From first dose of study drug in treatment period 1 to 8 days after the last dose; up to 18 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment A: Apremilast 30 mg Tablet - Fasted—0/34 (0%)5/34 (14.7%)
Treatment B: Apremilast 30 mg Oral Suspension - Fasted—0/34 (0%)10/34 (29.4%)
Treatment C: Apremilast 30 mg Oral Suspension - Fed—0/34 (0%)3/34 (8.8%)
Total—0/34 (0%)15/34 (44.1%)
Most frequent other events
Most frequent other events
EventTreatment A: Apremilast 30 mg Tablet - FastedTreatment B: Apremilast 30 mg Oral Suspension - FastedTreatment C: Apremilast 30 mg Oral Suspension - FedTotal
DiarrhoeaGastrointestinal disorders0/345/341/345/34
NauseaGastrointestinal disorders2/342/340/344/34
HeadacheNervous system disorders2/342/342/344/34
ConstipationGastrointestinal disorders0/342/341/343/34
DyspepsiaGastrointestinal disorders1/341/340/342/34
FlatulenceGastrointestinal disorders0/341/341/342/34
Feeling hotGeneral disorders0/342/340/342/34
Musculoskeletal painMusculoskeletal and connective tissue disorders1/341/340/342/34

Baseline characteristics

All randomized participants

Age, Continuous
Age, Continuous(years)Total
Mean33.3 (19 to 54)
Sex: Female, Male
Sex: Female, Male(Participants)Total
Female9
Male25
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Total
Hispanic or Latino1
Not Hispanic or Latino33
Unknown or Not Reported0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Total
American Indian or Alaska Native1
Asian1
Black or African American14
White17
Other1
08

Study locations

1 site
  • Covance Clinical Research Unit Inc
    Madison, Wisconsin 53704, United States
09

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2016 to primary completion in Feb 2016, 1 month.

Results were first posted in Aug 2021, 5 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2015
First posted
Dec 29, 2015
StartActual
Jan 5, 2016
Primary completionActual
Feb 27, 2016
CompletionActual
Feb 27, 2016
Results first posted
Aug 5, 2021
Last update
Aug 5, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02641353
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Dec 29, 2015
Start date
Jan 5, 2016
Primary completion
Feb 27, 2016
Completion
Feb 27, 2016
Results posted
Aug 5, 2021
Last update
Aug 5, 2021

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apremilast

Start the discussion